Humacyte Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $2.1MTTM through 30 Jun 2026
Net Income -$96.7MTTM through 30 Jun 2026
Free Cash Flow -$97.6MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Operating Margin | -5,306.0% |
| Net Margin | -4,560.8% |
Returns
-35.1%ROA
Balance Sheet Health
Debt / Equity11.40x
Current Ratio3.69x
Net Debt$30.4M
Cash & Equivalents$79.9M
Quality Metrics
Altman Z-Score-8.98
Piotroski F-Score3 / 9
FCF Margin-4,599.7%
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $2M
Diluted EPS-$0.52TTMFY2025: $-0.26
Dividend
No dividend
Capital Allocation
Capex Intensity17.3%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Product Revenue (Symvess) | $1.4M | View detailsCommercial traction is expected to expand as hospital and VA committee approvals increase. | |
| Contract Revenue | $649K | View detailsContract revenue is subject to phase completions and collaborative milestones. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.